Journal
ALZHEIMERS & DEMENTIA
Volume 9, Issue 1, Pages S21-S31Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2012.05.2187
Keywords
Alzheimer's disease; MCI; Mild cognitive impairment; ADAS-Cog; Composite endpoints; Novel endpoints; Clinical trials; Power; Sample size; Ceiling effects
Categories
Funding
- ADNI (National Institutes of Health [NIH]) [U01 AG024904]
- National Institute on Aging
- National Institute of Biomedical Imaging and Bioengineering
- Abbott
- AstraZeneca AB
- Bayer Schering Pharma AG
- Bristol-Myers Squibb
- Eisai Global Clinical Development
- Elan Corporation
- Eli Lilly and Company
- F. Hoffman-La Roche
- GE Healthcare
- Genentech
- GlaxoSmithKline
- Innogenetics
- Johnson and Johnson
- Medpace, Inc.
- Merck and Company, Inc.
- Novartis AG
- Pfizer, Inc.
- Schering-Plough
- Synarc, Inc.
- Alzheimer's Association and Alzheimer's Drug Discovery Foundation
- U.S. Food and Drug Administration
- NIH [P30 AG010129, K01 AG030514]
- Dana Foundation
Ask authors/readers for more resources
Background: The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) has been used widely as a cognitive end point in Alzheimer's Disease (AD) clinical trials. Efforts to treat AD pathology at earlier stages have also used ADAS-Cog, but failure in these trials can be difficult to interpret because the scale has well-known ceiling effects that limit its use in mild cognitive impairment (MCI) and early AD. A wealth of data exists in ADAS-Cog from both historical trials and contemporary longitudinal natural history studies that can provide insights about parts of the scale that may be better suited for MCI and early AD trials. Methods: Using Alzheimer's Disease Neuroimaging Initiative study data, we identified the most informative cognitive measures from the ADAS-Cog and other available scales. We used cross-sectional analyses to characterize trajectories of ADAS-Cog and its individual subscales, as well as other cognitive, functional, or global measures across disease stages. Informative measures were identified based on standardized mean of 2-year change from baseline and were combined into novel composite endpoints. We assessed performance of the novel endpoints based on sample size requirements for a 2-year clinical trial. A bootstrap validation procedure was also undertaken to assess the reproducibility of the standardized mean changes of the selected measures and the corresponding composites. Results: All proposed novel endpoints have improved standardized mean changes and thus improved statistical power compared with the ADAS-Cog 11. Further improvements were achieved by using cognitive-functional composites. Combining the novel composites with an enrichment strategy based on cerebral spinal fluid beta-amyloid (A beta(1-42)) in a 2-year trial yielded gains in power of 20% to 40% over ADAS-Cog 11, regardless of the novel measure considered. Conclusion: An empirical, data-driven approach with existing instruments was used to derive novel composite scales based on ADAS-Cog 11 with improved performance characteristics for MCI and early AD clinical trials. Together with patient enrichment based on A beta(1-42) pathology, these modified endpoints may allow more efficient clinical trials in these populations and can be assessed without modifying current test administration procedures in ongoing trials. (C) 2013 The Alzheimer's Association. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available